Early Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with prostate cancer (a specific type called adenocarcinoma) and are scheduled to receive external beam radiation therapy, possibly with or without hormone therapy, at the Wilmot Cancer Institute Department of Radiation Oncology
- Your cancer has not spread to other parts of the body, based on standard imaging scans
- You are able to read English
- You are in a general state of health and mental wellbeing that allows you to complete the study and attend follow-up appointments
- You are aged 18 or older but under 70 years old
- You have a reasonable level of physical functioning in daily life (confirm with trial site)
- Your kidneys are working well enough, based on a blood test taken within 30 days before joining
- Your blood counts (red blood cells and platelets) and liver function are at acceptable levels, based on tests taken within 90 days before joining, without needing recent transfusions or boosting medications
- Your resting blood pressure reading (the top number) is above 130
Who may not be able to join:
- You have previously had radiation therapy to the pelvic area
- You are currently taking or have taken lisinopril or a similar blood pressure/heart medication within the past two months (confirm with trial site)
- You have previously had an allergic reaction to lisinopril
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 585-275-7848
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean change in Expanded Prostate Index Composite score; change in the percentage of patients with positive blood test in urine; percentage of participants who achieve a dose of 20 mg
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.